查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602797

骨质疏鬆症药物和骨折药物市场：按药物、给药途径和分销分类 - 全球预测 2025-2030

Anti-Osteoporosis Therapy & Fracture Healing Market by Drug (Alendronate, Biophosphonates, Ibandronate), Route Of Administration (Injectable, Oral), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年骨质疏鬆和骨折药物市场规模为138亿美元，预计2024年将达到149.7亿美元，复合年增长率为8.53%，2030年将达到244.8亿美元。

抗骨质疏鬆治疗和骨折治疗市场着重于防止骨骼密度流失和改善骨折恢復的治疗，特别是对于患有骨质疏鬆症（骨骼变弱的疾病）的患者。该市场是由人口老化加剧、骨质疏鬆症和相关骨折盛行率增加以及药物治疗和医疗设备的进步所推动的。这些治疗方法对于降低与骨折相关的医疗费用和改善患者的生活品质至关重要。其应用范围涵盖医院、整形外科诊所和居家医疗，提供双磷酸盐、荷尔蒙补充疗法和不断增长的用于骨折癒合的生物材料等治疗方法。关键的成长要素包括技术进步、骨骼健康意识的提高以及向微创治疗的转变。最新的机会在于个人化医疗和生技药品，这得益于骨骼健康所涉及的遗传因素和细胞机制的持续研究。公司可以透过策略伙伴关係、研发投资来利用这些趋势。然而，市场面临着治疗成本上升、潜在的治疗副作用、严格的监管核准以及来自替代疗法和补充品的竞争等挑战。需要技术创新的领域包括开发新的药物传输系统、组织工程以及以干细胞和生长因子为重点的再生医学技术。此外，用于早期检测骨质疏鬆症的诊断工具的改进提供了巨大的业务成长潜力。该市场高度动态，其特点是密集的研发和不断变化的监管环境，要求公司保持敏捷性和适应性。在这种环境下，采取积极主动的策略来解决消费者教育方面的差异，同时创造具有成本效益、安全且高效的解决方案，对于成功至关重要。相关人员必须培养与医疗保健提供者和政策制定者的关係，以促进患者获得治疗并支持治疗计划中的明智决策。

主要市场统计
基准年[2023] 138亿美元
预测年份 [2024] 149.7亿美元
预测年份 [2030] 244.8亿美元
复合年增长率（%） 8.53%

市场动态：快速发展的骨质疏鬆症和骨折药物市场的关键市场洞察

供需的动态交互作用正在改变骨质疏鬆症和骨折药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 世界老年人口的增加
    • 由于快速都市化和生活方式的改变，骨骼疾病增加
    • 女性停经后骨质疏鬆症增加
  • 市场限制因素
    • 抗骨质疏鬆和骨折治疗药物高成本
  • 市场机会
    • 新药引进的研发成长
    • 提高对骨质疏鬆症及其对健康影响的认识
  • 市场挑战
    • 与抗骨质疏鬆药物和骨折癒合相关的併发症和副作用

波特五力：驾驭骨质疏鬆症与骨折药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨质疏鬆药物和骨折药物市场的外部影响

外部宏观环境因素在塑造骨质疏鬆药物和骨折药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解骨质疏鬆症治疗和骨折治疗药物市场的竞争状况

骨质疏鬆症药物和骨折治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵骨质疏鬆药物和骨折药物市场供应商的绩效评估

FPNV定位矩阵是评估骨质疏鬆药物和骨折药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划骨质疏鬆症和骨折治疗市场的成功之路

对骨质疏鬆症药物和骨折治疗药物市场进行策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地人口老化仍在持续
      • 由于快速的都市化和生活方式的改变，

骨病的发生

      • 女性停经后骨质疏鬆症发生率增加
    • 抑制因素
      • 骨质疏鬆症和骨折药物的高昂费用
    • 机会
      • 扩大新药引进的研究与开发
      • 持续认识骨质疏鬆症及其对健康的影响
    • 任务
      • 与骨质疏鬆药物和骨折癒合相关的併发症和副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按药物分類的骨质疏鬆症治疗药物和骨折治疗药物市场

  • 阿崙膦酸钠
  • 生物磷酸盐
  • Ibandronate sodium
  • 利塞膦酸盐
  • 选择性雌激素受体调节
    • Raloxifene
    • 锶兰雷特
  • Zoledronic acid

第七章骨质疏鬆药物和骨折药物市场：依给药途径

  • 可注射的
  • 口服

第八章 骨质疏鬆症治疗药物和骨折治疗药物市场经销商

  • 药局
  • 电子商务市场
  • 医院
  • 私人诊所
  • 零售药房

第九章北美和南美骨质疏鬆和骨折药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太骨质疏鬆药物与骨折药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的骨质疏鬆和骨折药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Healthy Life Pharma Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Sanofi SA
  • Taj Pharmaceuticals
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market was valued at USD 13.80 billion in 2023, expected to reach USD 14.97 billion in 2024, and is projected to grow at a CAGR of 8.53%, to USD 24.48 billion by 2030.

The anti-osteoporosis therapy and fracture healing market focuses on treatments that prevent bone density loss and improve recovery from bone fractures, especially for individuals with osteoporosis, a condition that weakens bones. This market is driven by a rising aging population, increased prevalence of osteoporosis and associated fractures, and advancements in pharmaceutical therapies and medical devices. These therapies are essential for reducing healthcare costs associated with fractures and improving the quality of life for patients. Their application spans hospitals, orthopedic clinics, and home healthcare, offering treatments like bisphosphonates, hormone replacement therapies, and growth in biomaterials used in fracture healing. Key growth influences include technological advancements, increased awareness about bone health, and a shift towards minimally invasive treatments. Latest opportunities lie in personalized medicine and biologics, driven by ongoing research on genetic factors and cellular mechanisms involved in bone health. Companies can capitalize on these trends through strategic partnerships, research, and development investment. However, the market faces challenges, such as high treatment costs, potential side effects of therapies, stringent regulatory approvals, and competition from alternative therapies and supplements. Areas ripe for innovation include the development of novel drug delivery systems, tissue engineering, and regenerative medicine techniques focusing on stem cells and growth factors. Additionally, improving diagnostic tools for early osteoporosis detection can offer substantial business growth potential. The market is highly dynamic, characterized by intensive R&D and evolving regulatory landscapes, requiring companies to remain agile and adaptive. Proactive strategies producing cost-effective, safe, and efficient solutions while addressing consumer education gaps are crucial for thriving in this environment. Stakeholders need to foster relationships with healthcare providers and policymakers to facilitate patient access and support informed decision-making in treatment planning.

KEY MARKET STATISTICS
Base Year [2023] USD 13.80 billion
Estimated Year [2024] USD 14.97 billion
Forecast Year [2030] USD 24.48 billion
CAGR (%) 8.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Osteoporosis Therapy & Fracture Healing Market

The Anti-Osteoporosis Therapy & Fracture Healing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide
    • Rapid urbanization coupled with changing lifestyle is increasing the occurrence of bone diseases
    • Growing incidences of postmenopausal osteoporosis in women
  • Market Restraints
    • High cost of the anti-osteoporosis medications & fracture healing treatments
  • Market Opportunities
    • Growing research and development in introduction of new drugs
    • Ongoing awareness of osteoporosis and its impact on health
  • Market Challenges
    • Complication and side effects related to with anti-osteoporosis medications & fracture healing

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Osteoporosis Therapy & Fracture Healing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Osteoporosis Therapy & Fracture Healing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Osteoporosis Therapy & Fracture Healing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Osteoporosis Therapy & Fracture Healing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Osteoporosis Therapy & Fracture Healing Market

A detailed market share analysis in the Anti-Osteoporosis Therapy & Fracture Healing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Osteoporosis Therapy & Fracture Healing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Osteoporosis Therapy & Fracture Healing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Osteoporosis Therapy & Fracture Healing Market

A strategic analysis of the Anti-Osteoporosis Therapy & Fracture Healing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Osteoporosis Therapy & Fracture Healing Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Healthy Life Pharma Pvt. Ltd., Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, Merck & Co., Inc., Novartis AG, Pfizer Inc., Salvavidas Pharmaceutical Private Limited, Sanofi S.A., Taj Pharmaceuticals, Taj Pharmaceuticals Limited, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Osteoporosis Therapy & Fracture Healing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Alendronate, Biophosphonates, Ibandronate, Risedronate, Selective Oestrogen Receptor Modulators, and Zoledronic Acid. The Selective Oestrogen Receptor Modulators is further studied across Raloxifene and Strontium Ranelete.
  • Based on Route Of Administration, market is studied across Injectable and Oral.
  • Based on Distribution, market is studied across Drug Stores, E-Commerce Market, Hospitals, Private Clinics, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide
      • 5.1.1.2. Rapid urbanization coupled with changing lifestyle is increasing the

occurrence of bone diseases

      • 5.1.1.3. Growing incidences of postmenopausal osteoporosis in women
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the anti-osteoporosis medications & fracture healing treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research and development in introduction of new drugs
      • 5.1.3.2. Ongoing awareness of osteoporosis and its impact on health
    • 5.1.4. Challenges
      • 5.1.4.1. Complication and side effects related to with anti-osteoporosis medications & fracture healing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Osteoporosis Therapy & Fracture Healing Market, by Drug

  • 6.1. Introduction
  • 6.2. Alendronate
  • 6.3. Biophosphonates
  • 6.4. Ibandronate
  • 6.5. Risedronate
  • 6.6. Selective Oestrogen Receptor Modulators
    • 6.6.1. Raloxifene
    • 6.6.2. Strontium Ranelete
  • 6.7. Zoledronic Acid

7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Distribution

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce Market
  • 8.4. Hospitals
  • 8.5. Private Clinics
  • 8.6. Retail Pharmacies

9. Americas Anti-Osteoporosis Therapy & Fracture Healing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Eli Lilly and Company
  • 3. F. Hoffmann-La Roche Ltd.
  • 4. GlaxoSmithKline plc
  • 5. Healthy Life Pharma Pvt. Ltd.
  • 6. Johnson & Johnson Services, Inc.
  • 7. Manus Aktteva Biopharma LLP
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Salvavidas Pharmaceutical Private Limited
  • 12. Sanofi S.A.
  • 13. Taj Pharmaceuticals
  • 14. Taj Pharmaceuticals Limited
  • 15. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BIOPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STRONTIUM RANELETE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY E-COMMERCE MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023